- Home
- ARI vs CDTX Comparison
ARI vs CDTX Comparison
Compare ARI & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARI
- CDTX
- Stock Information
- Founded
- ARI 2009
- CDTX 2012
- Country
- ARI United States
- CDTX United States
- Employees
- ARI N/A
- CDTX N/A
- Industry
- ARI Real Estate Investment Trusts
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARI Real Estate
- CDTX Health Care
- Exchange
- ARI Nasdaq
- CDTX Nasdaq
- Market Cap
- ARI 1.5B
- CDTX 1.6B
- IPO Year
- ARI 2009
- CDTX 2015
- Fundamental
- Price
- ARI $10.53
- CDTX $64.85
- Analyst Decision
- ARI Hold
- CDTX Strong Buy
- Analyst Count
- ARI 4
- CDTX 11
- Target Price
- ARI $10.08
- CDTX $57.00
- AVG Volume (30 Days)
- ARI 728.5K
- CDTX 493.2K
- Earning Date
- ARI 10-29-2025
- CDTX 11-06-2025
- Dividend Yield
- ARI 9.52%
- CDTX N/A
- EPS Growth
- ARI N/A
- CDTX N/A
- EPS
- ARI N/A
- CDTX N/A
- Revenue
- ARI $273,783,000.00
- CDTX N/A
- Revenue This Year
- ARI $26.08
- CDTX N/A
- Revenue Next Year
- ARI $18.31
- CDTX N/A
- P/E Ratio
- ARI N/A
- CDTX N/A
- Revenue Growth
- ARI 55.89
- CDTX N/A
- 52 Week Low
- ARI $7.70
- CDTX $10.14
- 52 Week High
- ARI $11.11
- CDTX $69.36
- Technical
- Relative Strength Index (RSI)
- ARI 50.26
- CDTX 54.45
- Support Level
- ARI $10.47
- CDTX $61.10
- Resistance Level
- ARI $11.11
- CDTX $69.21
- Average True Range (ATR)
- ARI 0.18
- CDTX 3.28
- MACD
- ARI -0.05
- CDTX -0.25
- Stochastic Oscillator
- ARI 27.50
- CDTX 47.09
About ARI Apollo Commercial Real Estate Finance Inc
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that primarily originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.